For the quarter ending 2025-12-31, EDSA made $102,472 in revenue. -$2,252,984 in net income. Net profit margin of -2198.63%.
| Income Statement | 2025-12-31 | 2025-09-30 | 2025-06-30 | |
|---|---|---|---|---|
| Research and development | 1,124,727 | 909,890.333 | 939,067 | |
| General and administrative | 1,216,656 | 1,092,717.333 | 964,676 | |
| Loss from operations | -2,341,383 | -2,002,607.667 | -1,903,743 | |
| Misc other income | - | 0 | 0 | |
| Reimbursement grant income | 102,425 | 200,204.333 | 183,281 | |
| Interest income | 47 | 662 | 572 | |
| Foreign exchange loss | -8,758 | -10,011.667 | -29,574 | |
| Nonoperating income (expense) | 93,714 | 190,854.667 | 154,279 | |
| Loss before income taxes | - | -1,811,753 | -1,749,464 | |
| Income tax expense | - | 266.667 | 0 | |
| Net loss | -2,247,669 | -1,816,845.333 | -1,749,464 | |
| Exchange differences on translation | -5,315 | -29,256.333 | 164,611 | |
| Net comprehensive loss | -2,252,984 | -1,838,382.333 | -1,584,853 | |
| Loss per common share - basic and diluted (in dollars per share) | -0.28 | -0.34 | -0.25 | |
| Weighted average number of common shares (in shares) | 7,972,532 | -448,656.667 | 7,022,678 | |
Edesa Biotech, Inc. (EDSA)
Edesa Biotech, Inc. (EDSA)